Name | Number of supported studies | Average coverage | |
---|---|---|---|
B cell | 26 studies | 28% ± 9% | |
plasma cell | 19 studies | 34% ± 8% | |
naive B cell | 16 studies | 28% ± 13% | |
memory B cell | 13 studies | 27% ± 12% | |
IgG plasma cell | 10 studies | 44% ± 22% | |
IgA plasma cell | 9 studies | 42% ± 20% | |
plasmablast | 7 studies | 33% ± 12% | |
precursor B cell | 4 studies | 33% ± 18% | |
immature B cell | 4 studies | 42% ± 13% | |
IgM plasma cell | 4 studies | 41% ± 13% | |
T cell | 3 studies | 30% ± 6% | |
plasmacytoid dendritic cell | 3 studies | 26% ± 8% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
intestine | 3 studies | 37% ± 23% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 92% | 3313.57 | 532 / 578 | 82% | 1583.62 | 949 / 1155 |
stomach | 74% | 3842.53 | 266 / 359 | 59% | 721.42 | 170 / 286 |
intestine | 56% | 5933.61 | 539 / 966 | 58% | 619.30 | 304 / 527 |
spleen | 100% | 25461.80 | 241 / 241 | 0% | 0 | 0 / 0 |
breast | 47% | 1739.67 | 215 / 459 | 51% | 650.46 | 570 / 1118 |
bladder | 33% | 1119.95 | 7 / 21 | 50% | 494.80 | 251 / 504 |
peripheral blood | 81% | 3257.13 | 751 / 929 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 80% | 2161.42 | 36 / 45 |
liver | 59% | 665.21 | 133 / 226 | 16% | 141.30 | 65 / 406 |
uterus | 24% | 237.47 | 40 / 170 | 47% | 603.41 | 214 / 459 |
kidney | 46% | 1367.60 | 41 / 89 | 23% | 292.26 | 209 / 901 |
esophagus | 25% | 539.02 | 356 / 1445 | 44% | 439.38 | 80 / 183 |
pancreas | 12% | 112.57 | 39 / 328 | 56% | 512.69 | 100 / 178 |
thymus | 32% | 1712.82 | 212 / 653 | 34% | 449.46 | 207 / 605 |
lymph node | 0% | 0 | 0 / 0 | 66% | 1221.75 | 19 / 29 |
ovary | 22% | 195.36 | 39 / 180 | 37% | 430.66 | 159 / 430 |
skin | 5% | 41.89 | 97 / 1809 | 50% | 924.58 | 235 / 472 |
prostate | 38% | 527.84 | 92 / 245 | 13% | 72.63 | 65 / 502 |
adipose | 27% | 466.30 | 331 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 22% | 484.19 | 296 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 11% | 301.55 | 29 / 258 | 9% | 81.65 | 20 / 230 |
heart | 5% | 53.25 | 47 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 4% | 154.65 | 3 / 80 |
brain | 0% | 4.33 | 11 / 2642 | 2% | 5.21 | 11 / 705 |
muscle | 1% | 8.23 | 8 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002250 | Biological process | adaptive immune response |
GO_0050853 | Biological process | B cell receptor signaling pathway |
GO_0016064 | Biological process | immunoglobulin mediated immune response |
GO_0005615 | Cellular component | extracellular space |
GO_0071735 | Cellular component | IgG immunoglobulin complex |
GO_0071745 | Cellular component | IgA immunoglobulin complex |
GO_0072562 | Cellular component | blood microparticle |
GO_0070062 | Cellular component | extracellular exosome |
GO_0071753 | Cellular component | IgM immunoglobulin complex |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0071742 | Cellular component | IgE immunoglobulin complex |
GO_0071738 | Cellular component | IgD immunoglobulin complex |
GO_0003823 | Molecular function | antigen binding |
Gene name | IGLC3 |
Protein name | Immunoglobulin lambda constant 3 (Ig lambda chain C region DOT) (Ig lambda chain C region NEWM) (Ig lambda-3 chain C regions) |
Synonyms | |
Description | FUNCTION: Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens . The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen . . |
Accessions | P0DOY3 ENST00000390325.2 |